EXACT Sciences to Webcast Panel Presentation at the 2007 RBC Capital Markets Healthcare Conference

Business Wire, Dec 5, 2007

MARLBOROUGH, Mass. -- EXACT Sciences Corporation (NASDAQ: EXAS) announced today that Jeffrey R. Luber, EXACT Sciences' President, is scheduled to participate in the panel discussion "The Future of Diagnostic Medicine: High Fidelity Testing" on Wednesday, December 12, 2007 at 3:30p.m., ET as part of the 2007 RBC Capital Markets Healthcare Conference being held at the Westin New York at Times Square Hotel in New York City.

The panel discussion will be webcast live. The webcast may be accessed by visiting the Investors' section of the Company's website, www.exactsciences.com. An archived version of the webcast will be available for 30 days following the live presentation.

EXACT Sciences Corporation

EXACT Sciences Corporation uses applied genomics to develop screening technologies for use in the detection of cancer. The Company's primary focus since inception has been on developing screening technologies for colorectal cancer. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than 20 years, screening rates for colorectal cancer remain low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based, non-invasive technologies will help promote increased screening for colorectal cancer. EXACT Sciences is based in Marlborough, Mass.

Certain statements made in this press release that are not based on historical information are express or implied forward-looking statements relating to, among other things, EXACT Sciences' expectations concerning the timing and content of corporate presentations. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond EXACT Sciences' control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. EXACT Sciences undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by EXACT Sciences, see the disclosure contained in EXACT Sciences' public filings with the Securities and Exchange Commission including, without limitation, its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the SEC.